These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22153341)

  • 1. Effect of a second nitroimidazole redox centre on the accumulation of a hypoxia marker: synthesis and in vitro evaluation of 99mTc-labeled bisnitroimidazole propylene amine oxime complexes.
    Huang H; Zhou H; Li Z; Wang X; Chu T
    Bioorg Med Chem Lett; 2012 Jan; 22(1):172-7. PubMed ID: 22153341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving tumor/muscle and tumor/blood ratios of
    Li S; Chu T
    Bioorg Med Chem Lett; 2023 Feb; 82():129154. PubMed ID: 36736496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evaluation of technetium-99m-labeled propylene amine oxime complexes containing nitroimidazole and nitrotriazole groups as hypoxia markers.
    Zhang Q; Huang H; Chu T
    J Labelled Comp Radiopharm; 2016 Jan; 59(1):14-23. PubMed ID: 26690916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and bioevaluation of a novel
    Li S; Chu T
    Bioorg Med Chem Lett; 2024 Jul; 106():129773. PubMed ID: 38677561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction.
    Linder KE; Chan YW; Cyr JE; Malley MF; Nowotnik DP; Nunn AD
    J Med Chem; 1994 Jan; 37(1):9-17. PubMed ID: 8289205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and bioevaluation of the cyclopentadienyl tricarbonyl technetium-99m 2-nitroimidazole derivatives for tumor hypoxia imaging.
    Su H; Chu T
    Bioorg Med Chem Lett; 2022 Mar; 60():128583. PubMed ID: 35085720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics.
    Melo T; Hua HA; Ballinger JR; Rauth AM
    Biochem Pharmacol; 1997 Sep; 54(6):685-93. PubMed ID: 9310345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, radiolabeling and biological evaluation of propylene amine oxime complexes containing nitrotriazoles as hypoxia markers.
    Huang H; Mei L; Chu T
    Molecules; 2012 Jun; 17(6):6808-20. PubMed ID: 22664468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ⁹⁹mTc/Re complexes bearing bisnitroimidazole or mononitroimidazole as potential bioreductive markers for tumor: synthesis, physicochemical characterization and biological evaluation.
    Mei L; Wang Y; Chu T
    Eur J Med Chem; 2012 Dec; 58():50-63. PubMed ID: 23088932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: effect of lipophilicity.
    Zhang X; Su ZF; Ballinger JR; Rauth AM; Pollak A; Thornback JR
    Bioconjug Chem; 2000; 11(3):401-7. PubMed ID: 10821657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study on nitroimidazole-99mTc(CO)3 complexes as hypoxia marker: some observations towards possible improvement in in vivo efficacy.
    Mallia MB; Subramanian S; Mathur A; Sarma HD; Banerjee S
    Nucl Med Biol; 2014 Aug; 41(7):600-10. PubMed ID: 24856280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary studies of 99mTc-BnAO and its analogues: synthesis, radiolabeling and in vitro cell uptake.
    Sun X; Chu T; Wang X
    Nucl Med Biol; 2010 Feb; 37(2):117-23. PubMed ID: 20152710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of a putative hypoxic tissue marker, technetium-99m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic and stunned myocardium.
    Kusuoka H; Hashimoto K; Fukuchi K; Nishimura T
    J Nucl Med; 1994 Aug; 35(8):1371-6. PubMed ID: 8046496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A thiourea-bridged
    Mittal S; Kumar C; Jha L; Mallia MB
    Drug Dev Res; 2024 Sep; 85(6):e22258. PubMed ID: 39253992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia.
    Ballinger JR; Kee JW; Rauth AM
    J Nucl Med; 1996 Jun; 37(6):1023-31. PubMed ID: 8683295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia.
    Melo T; Ballinger JR; Rauth AM
    Biochem Pharmacol; 2000 Sep; 60(5):625-34. PubMed ID: 10927020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel amine-dioxime chelator for technetium-99m: synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells.
    Su ZF; Ballinger JR; Rauth AM; Abrams DN; Billinghurst MW
    Bioconjug Chem; 2000; 11(5):652-63. PubMed ID: 10995208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia.
    Su ZF; Zhang X; Ballinger JR; Rauth AM; Pollak A; Thornback JR
    Bioconjug Chem; 1999; 10(5):897-904. PubMed ID: 10502359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of a new 99mTc(I)-tricarbonyl complex bearing the 5-nitroimidazol-1-yl moiety as potential hypoxia imaging agent.
    Giglio J; Dematteis S; Fernández S; Cerecetto H; Rey A
    J Labelled Comp Radiopharm; 2014 May; 57(6):403-9. PubMed ID: 24692093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biological characterization of (99m)Tc-BnAO-NI as a SPECT probe for imaging hypoxia in a sarcoma-bearing mouse model.
    Hsia CC; Huang FL; Hung GU; Shen LH; Chen CL; Wang HE
    Appl Radiat Isot; 2011 Apr; 69(4):649-55. PubMed ID: 21236690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.